Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bioxyne Limited ( (AU:BXN) ) has shared an update.
Bioxyne director Samuel Watson has increased his indirect shareholding in the company through an on-market purchase conducted via Breathe International Limited, a company in which he holds a controlling interest. The acquisition involved 1.8 million ordinary shares for a consideration of $90,000, slightly lifting Breathe International’s total holding in Bioxyne.
Following the transaction, Breathe International’s stake rose to 578,068,527 shares, while Watson’s direct holding of 34,499,362 shares and 39 million performance rights in Bioxyne remained unchanged. The trade did not occur during a closed period, suggesting routine portfolio adjustment rather than a time-sensitive or exceptional dealing by the director.
The most recent analyst rating on (AU:BXN) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Bioxyne Limited stock, see the AU:BXN Stock Forecast page.
More about Bioxyne Limited
Bioxyne Limited is an Australian-listed company, with disclosure lodged to the ASX indicating it operates under standard corporate governance and securities reporting obligations. The filing highlights the role of director Samuel Watson and his associated entities, Breathe International Limited and Zonetech Wellness Limited, as significant holders of Bioxyne shares.
Average Trading Volume: 3,132,309
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$115.7M
Find detailed analytics on BXN stock on TipRanks’ Stock Analysis page.